TickerFacts.

Exozymes Inc. (EXOZ): R&D Expense

Annual figures by period end, from SEC filings.

$3.71M
Year ended 2025-12-31
$4.89M
Trailing 12 months to 2026-06-30
2023-12-31: $527.5K2024-12-31: $1.87M2025-12-31: $3.71M$3.71M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$3.71M+98.4%2026-03-30, From 2025-01-01
2024-12-31$1.87M+254.3%2026-03-30, From 2024-01-01
2023-12-31$527.5Kn/a2025-03-31, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Exozymes Inc. (EXOZ)2025-12-31$3.71M+98.4%
AIM ImmunoTech Inc. (AIM)2025-12-31$3.92M-36.7%
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31$3.06M-14.6%
Silexion Therapeutics Corp (SLXN)2025-12-31$7.14M+22.8%
VivoSim Labs, Inc. (VIVS)2026-03-31$4.19M-16.6%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$2.26M-5.9%
Tevogen Inc. (TVGN)2025-12-31$11.11M-64.2%
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31$9.74M+9.7%
Greenland Mines Ltd (GRML)2025-12-31$634.2Kn/a

Compare EXOZ, AIM, ELOX, SLXN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗